ALSO READNewly-identified type 3c of diabetes is being wrongly diagnosed as type 2 Hot weather may increase diabetes risk during pregnancy: Study Soya beans, nuts may help prevent type 2 diabetes: Study Diabetes on rise among poor people in India, says Lancet study Roche Diabetes Care looks to double its retail presence in India
Drug firm Zydus on Friday said it has received approval from the Mexican regulatory authority to market Lipaglyn (Saroglitazar Magnesium) used for the treatment of dyslipidemia in patients with diabetes.
The company has been granted marketing approval from the Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk) to commercialise Lipaglyn in Mexico, Zydus said in a statement.
"Saroglitazar is an important scientific and medical breakthrough in our effort to develop medicines for patients suffering from hypertriglyceridemia and diabetic dyslipidemia," Zydus Group Chairman Pankaj Patel said.
This approval of Saroglitazar in Mexico is a major milestone for the company, he added.
"Lipaglyn is used for treatment of dyslipidemia in patients with diabetes mellitus type 2 and hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins," Zydus said.
Lipaglyn, a prescription drug, was first launched in India during September 2013, Zydus said.
"Over the last several years, more than 500,000 patients have been treated with Lipaglyn in India...," it added.
Shares of Cadila Healthcare, the listed entity of Zydus Group were today trading at Rs 467.50 per scrip on BSE, down 2.33 per cent from its previous close.